The highlights of the recent American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting tended to be data for approved drugs and therapies in later-stage development that back up previously reported efficacy or provide assurances about safety in rheumatoid and psoriatic arthritis and other autoimmune diseases.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?